3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urologic Neoplasms
2
Urologic Diseases
1
Urolithiasis
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Non-Muscle Invasive Bladder Neoplasms
1
Hydronephrosis
1
Fasting
1
Carcinoma, Transitional Cell
1
Interventions
Gemcitabine
30
Mitomycin
25
BCG Vaccine
13
Docetaxel
10
Epirubicin
6
erdafitinib
5
durvalumab
5
dodecyl maltoside
5
Radiotherapy
5
Cystoscopy
5
apaziquone
4
ALT-803
4
tislelizumab
3
5-aminolevulinic acid hexyl ester
3
viscum album peptide
2
pembrolizumab
2
disitamab vedotin
2
avelumab
2
VB4-845
2
Therapeutics
2
Imiquimod
2
Hyaluronic Acid
2
Administration, Intravesical
2
1-phenyl-3,3-dimethyltriazene
2
vocimagene amiretrorepvec
1
valrubicin
1
tremelimumab
1
toripalimab
1
pirarubicin
1
pemigatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non-Muscle Invasive Bladder Neoplasms
×
Water
×
Genitourinary
×
Clear all
NCT01803295
2017-06-16
OPTIMA
UroGen Pharma Ltd.
Phase NA
Completed
80 enrolled